nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—ADRB2—prostate cancer	0.369	1	CbGaD
Betaxolol—CYP1A2—Flutamide—prostate cancer	0.0595	0.206	CbGbCtD
Betaxolol—CYP2D6—Bicalutamide—prostate cancer	0.0591	0.205	CbGbCtD
Betaxolol—CYP2D6—Abiraterone—prostate cancer	0.049	0.17	CbGbCtD
Betaxolol—CYP1A2—Estrone—prostate cancer	0.043	0.149	CbGbCtD
Betaxolol—CYP1A2—Conjugated Estrogens—prostate cancer	0.0281	0.0975	CbGbCtD
Betaxolol—CYP1A2—Estradiol—prostate cancer	0.0247	0.0856	CbGbCtD
Betaxolol—CYP1A2—Etoposide—prostate cancer	0.0161	0.0559	CbGbCtD
Betaxolol—CYP2D6—Doxorubicin—prostate cancer	0.00906	0.0314	CbGbCtD
Betaxolol—Acebutolol—SLC22A1—prostate cancer	0.000506	0.103	CrCbGaD
Betaxolol—Chlorphenesin—CYP19A1—prostate cancer	0.000408	0.0834	CrCbGaD
Betaxolol—Esmolol—ADRB2—prostate cancer	0.000401	0.082	CrCbGaD
Betaxolol—Atenolol—ADRB2—prostate cancer	0.00035	0.0715	CrCbGaD
Betaxolol—Bisoprolol—ADRB2—prostate cancer	0.000341	0.0697	CrCbGaD
Betaxolol—Acebutolol—ADRB2—prostate cancer	0.000323	0.066	CrCbGaD
Betaxolol—Oxprenolol—ADRB2—prostate cancer	0.000321	0.0655	CrCbGaD
Betaxolol—Alprenolol—ADRB2—prostate cancer	0.000293	0.0599	CrCbGaD
Betaxolol—Metoprolol—ADRB2—prostate cancer	0.000273	0.0557	CrCbGaD
Betaxolol—Pindolol—ADRB2—prostate cancer	0.000252	0.0516	CrCbGaD
Betaxolol—Metoprolol—CYP2C19—prostate cancer	0.000235	0.048	CrCbGaD
Betaxolol—Chlorphenesin—CYP3A4—prostate cancer	0.000192	0.0392	CrCbGaD
Betaxolol—Chlorphenesin—PTGS2—prostate cancer	0.000188	0.0383	CrCbGaD
Betaxolol—Bisoprolol—CYP3A4—prostate cancer	0.000187	0.0382	CrCbGaD
Betaxolol—Propranolol—CYP3A5—prostate cancer	0.000174	0.0356	CrCbGaD
Betaxolol—Propranolol—ADRB2—prostate cancer	0.000138	0.0281	CrCbGaD
Betaxolol—Propranolol—CYP2C19—prostate cancer	0.000119	0.0242	CrCbGaD
Betaxolol—Propranolol—CYP1A1—prostate cancer	0.000118	0.0241	CrCbGaD
Betaxolol—Propranolol—CYP3A4—prostate cancer	7.54e-05	0.0154	CrCbGaD
Betaxolol—Vertigo—Prednisone—prostate cancer	5.03e-05	0.0002	CcSEcCtD
Betaxolol—Thrombocytopenia—Capecitabine—prostate cancer	5.02e-05	0.000199	CcSEcCtD
Betaxolol—Syncope—Prednisone—prostate cancer	5.02e-05	0.000199	CcSEcCtD
Betaxolol—Tachycardia—Capecitabine—prostate cancer	5e-05	0.000199	CcSEcCtD
Betaxolol—Hypoaesthesia—Epirubicin—prostate cancer	5e-05	0.000199	CcSEcCtD
Betaxolol—Pharyngitis—Epirubicin—prostate cancer	4.99e-05	0.000198	CcSEcCtD
Betaxolol—Skin disorder—Capecitabine—prostate cancer	4.98e-05	0.000198	CcSEcCtD
Betaxolol—Sweating—Doxorubicin—prostate cancer	4.97e-05	0.000197	CcSEcCtD
Betaxolol—Hyperhidrosis—Capecitabine—prostate cancer	4.95e-05	0.000197	CcSEcCtD
Betaxolol—Hypotension—Docetaxel—prostate cancer	4.95e-05	0.000196	CcSEcCtD
Betaxolol—Loss of consciousness—Prednisone—prostate cancer	4.92e-05	0.000195	CcSEcCtD
Betaxolol—Epistaxis—Doxorubicin—prostate cancer	4.89e-05	0.000194	CcSEcCtD
Betaxolol—Anorexia—Capecitabine—prostate cancer	4.89e-05	0.000194	CcSEcCtD
Betaxolol—Nausea—Estradiol—prostate cancer	4.88e-05	0.000194	CcSEcCtD
Betaxolol—Vomiting—Mitoxantrone—prostate cancer	4.87e-05	0.000193	CcSEcCtD
Betaxolol—Sinusitis—Doxorubicin—prostate cancer	4.86e-05	0.000193	CcSEcCtD
Betaxolol—Visual impairment—Epirubicin—prostate cancer	4.84e-05	0.000192	CcSEcCtD
Betaxolol—Agranulocytosis—Doxorubicin—prostate cancer	4.83e-05	0.000192	CcSEcCtD
Betaxolol—Rash—Mitoxantrone—prostate cancer	4.83e-05	0.000192	CcSEcCtD
Betaxolol—Dermatitis—Mitoxantrone—prostate cancer	4.82e-05	0.000192	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.82e-05	0.000191	CcSEcCtD
Betaxolol—Headache—Mitoxantrone—prostate cancer	4.8e-05	0.00019	CcSEcCtD
Betaxolol—Hypotension—Capecitabine—prostate cancer	4.79e-05	0.00019	CcSEcCtD
Betaxolol—Insomnia—Docetaxel—prostate cancer	4.79e-05	0.00019	CcSEcCtD
Betaxolol—Arthralgia—Prednisone—prostate cancer	4.76e-05	0.000189	CcSEcCtD
Betaxolol—Myalgia—Prednisone—prostate cancer	4.76e-05	0.000189	CcSEcCtD
Betaxolol—Paraesthesia—Docetaxel—prostate cancer	4.75e-05	0.000189	CcSEcCtD
Betaxolol—Anxiety—Prednisone—prostate cancer	4.75e-05	0.000188	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—prostate cancer	4.73e-05	0.000188	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.73e-05	0.000188	CcSEcCtD
Betaxolol—Dyspnoea—Docetaxel—prostate cancer	4.72e-05	0.000187	CcSEcCtD
Betaxolol—Discomfort—Prednisone—prostate cancer	4.71e-05	0.000187	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—prostate cancer	4.7e-05	0.000186	CcSEcCtD
Betaxolol—Hypersensitivity—Etoposide—prostate cancer	4.69e-05	0.000186	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—prostate cancer	4.69e-05	0.000186	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.67e-05	0.000185	CcSEcCtD
Betaxolol—Flushing—Epirubicin—prostate cancer	4.66e-05	0.000185	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—prostate cancer	4.66e-05	0.000185	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—prostate cancer	4.66e-05	0.000185	CcSEcCtD
Betaxolol—Dyspepsia—Docetaxel—prostate cancer	4.66e-05	0.000185	CcSEcCtD
Betaxolol—Insomnia—Capecitabine—prostate cancer	4.64e-05	0.000184	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—prostate cancer	4.63e-05	0.000184	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—prostate cancer	4.62e-05	0.000183	CcSEcCtD
Betaxolol—Paraesthesia—Capecitabine—prostate cancer	4.6e-05	0.000183	CcSEcCtD
Betaxolol—Decreased appetite—Docetaxel—prostate cancer	4.6e-05	0.000183	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Docetaxel—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Betaxolol—Asthenia—Etoposide—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Betaxolol—Dyspnoea—Capecitabine—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Betaxolol—Oedema—Prednisone—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Betaxolol—Fatigue—Docetaxel—prostate cancer	4.56e-05	0.000181	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—prostate cancer	4.56e-05	0.000181	CcSEcCtD
Betaxolol—Nausea—Mitoxantrone—prostate cancer	4.55e-05	0.000181	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—prostate cancer	4.54e-05	0.00018	CcSEcCtD
Betaxolol—Infection—Prednisone—prostate cancer	4.54e-05	0.00018	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—prostate cancer	4.53e-05	0.00018	CcSEcCtD
Betaxolol—Pain—Docetaxel—prostate cancer	4.53e-05	0.00018	CcSEcCtD
Betaxolol—Constipation—Docetaxel—prostate cancer	4.53e-05	0.00018	CcSEcCtD
Betaxolol—Dyspepsia—Capecitabine—prostate cancer	4.51e-05	0.000179	CcSEcCtD
Betaxolol—Chills—Epirubicin—prostate cancer	4.51e-05	0.000179	CcSEcCtD
Betaxolol—Pruritus—Etoposide—prostate cancer	4.51e-05	0.000179	CcSEcCtD
Betaxolol—Shock—Prednisone—prostate cancer	4.49e-05	0.000178	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—prostate cancer	4.49e-05	0.000178	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—prostate cancer	4.48e-05	0.000178	CcSEcCtD
Betaxolol—Nervous system disorder—Prednisone—prostate cancer	4.48e-05	0.000178	CcSEcCtD
Betaxolol—Tachycardia—Prednisone—prostate cancer	4.46e-05	0.000177	CcSEcCtD
Betaxolol—Decreased appetite—Capecitabine—prostate cancer	4.46e-05	0.000177	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—prostate cancer	4.44e-05	0.000176	CcSEcCtD
Betaxolol—Skin disorder—Prednisone—prostate cancer	4.43e-05	0.000176	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Capecitabine—prostate cancer	4.42e-05	0.000176	CcSEcCtD
Betaxolol—Fatigue—Capecitabine—prostate cancer	4.42e-05	0.000175	CcSEcCtD
Betaxolol—Hyperhidrosis—Prednisone—prostate cancer	4.41e-05	0.000175	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—prostate cancer	4.4e-05	0.000175	CcSEcCtD
Betaxolol—Constipation—Capecitabine—prostate cancer	4.38e-05	0.000174	CcSEcCtD
Betaxolol—Pain—Capecitabine—prostate cancer	4.38e-05	0.000174	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—prostate cancer	4.38e-05	0.000174	CcSEcCtD
Betaxolol—Erythema—Epirubicin—prostate cancer	4.38e-05	0.000174	CcSEcCtD
Betaxolol—Feeling abnormal—Docetaxel—prostate cancer	4.36e-05	0.000173	CcSEcCtD
Betaxolol—Diarrhoea—Etoposide—prostate cancer	4.36e-05	0.000173	CcSEcCtD
Betaxolol—Anorexia—Prednisone—prostate cancer	4.35e-05	0.000173	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—prostate cancer	4.35e-05	0.000173	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—prostate cancer	4.34e-05	0.000172	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—prostate cancer	4.32e-05	0.000171	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—prostate cancer	4.32e-05	0.000171	CcSEcCtD
Betaxolol—Tension—Epirubicin—prostate cancer	4.29e-05	0.00017	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—prostate cancer	4.28e-05	0.00017	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—prostate cancer	4.25e-05	0.000169	CcSEcCtD
Betaxolol—Feeling abnormal—Capecitabine—prostate cancer	4.22e-05	0.000168	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—prostate cancer	4.22e-05	0.000167	CcSEcCtD
Betaxolol—Dizziness—Etoposide—prostate cancer	4.21e-05	0.000167	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—prostate cancer	4.21e-05	0.000167	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—prostate cancer	4.2e-05	0.000167	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—prostate cancer	4.19e-05	0.000166	CcSEcCtD
Betaxolol—Body temperature increased—Docetaxel—prostate cancer	4.18e-05	0.000166	CcSEcCtD
Betaxolol—Chills—Doxorubicin—prostate cancer	4.17e-05	0.000166	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Prednisone—prostate cancer	4.16e-05	0.000165	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—prostate cancer	4.15e-05	0.000165	CcSEcCtD
Betaxolol—Insomnia—Prednisone—prostate cancer	4.13e-05	0.000164	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—prostate cancer	4.12e-05	0.000164	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—prostate cancer	4.11e-05	0.000163	CcSEcCtD
Betaxolol—Paraesthesia—Prednisone—prostate cancer	4.1e-05	0.000163	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—prostate cancer	4.07e-05	0.000162	CcSEcCtD
Betaxolol—Urticaria—Capecitabine—prostate cancer	4.07e-05	0.000162	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—prostate cancer	4.06e-05	0.000161	CcSEcCtD
Betaxolol—Body temperature increased—Capecitabine—prostate cancer	4.05e-05	0.000161	CcSEcCtD
Betaxolol—Vomiting—Etoposide—prostate cancer	4.05e-05	0.000161	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—prostate cancer	4.05e-05	0.000161	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—prostate cancer	4.05e-05	0.000161	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—prostate cancer	4.04e-05	0.000161	CcSEcCtD
Betaxolol—Dyspepsia—Prednisone—prostate cancer	4.02e-05	0.00016	CcSEcCtD
Betaxolol—Rash—Etoposide—prostate cancer	4.02e-05	0.000159	CcSEcCtD
Betaxolol—Dermatitis—Etoposide—prostate cancer	4.01e-05	0.000159	CcSEcCtD
Betaxolol—Headache—Etoposide—prostate cancer	3.99e-05	0.000158	CcSEcCtD
Betaxolol—Tension—Doxorubicin—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Betaxolol—Decreased appetite—Prednisone—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—prostate cancer	3.96e-05	0.000157	CcSEcCtD
Betaxolol—Malaise—Epirubicin—prostate cancer	3.95e-05	0.000157	CcSEcCtD
Betaxolol—Fatigue—Prednisone—prostate cancer	3.94e-05	0.000156	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—prostate cancer	3.93e-05	0.000156	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—prostate cancer	3.93e-05	0.000156	CcSEcCtD
Betaxolol—Syncope—Epirubicin—prostate cancer	3.92e-05	0.000156	CcSEcCtD
Betaxolol—Constipation—Prednisone—prostate cancer	3.9e-05	0.000155	CcSEcCtD
Betaxolol—Hypersensitivity—Docetaxel—prostate cancer	3.9e-05	0.000155	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—prostate cancer	3.89e-05	0.000155	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—prostate cancer	3.87e-05	0.000153	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—prostate cancer	3.85e-05	0.000153	CcSEcCtD
Betaxolol—Cough—Epirubicin—prostate cancer	3.82e-05	0.000152	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—prostate cancer	3.82e-05	0.000151	CcSEcCtD
Betaxolol—Asthenia—Docetaxel—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Betaxolol—Nausea—Etoposide—prostate cancer	3.78e-05	0.00015	CcSEcCtD
Betaxolol—Hypersensitivity—Capecitabine—prostate cancer	3.78e-05	0.00015	CcSEcCtD
Betaxolol—Feeling abnormal—Prednisone—prostate cancer	3.76e-05	0.000149	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—prostate cancer	3.76e-05	0.000149	CcSEcCtD
Betaxolol—Pruritus—Docetaxel—prostate cancer	3.75e-05	0.000149	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—prostate cancer	3.74e-05	0.000149	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—prostate cancer	3.72e-05	0.000148	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—prostate cancer	3.72e-05	0.000148	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—prostate cancer	3.72e-05	0.000148	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—prostate cancer	3.71e-05	0.000147	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.7e-05	0.000147	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—prostate cancer	3.68e-05	0.000146	CcSEcCtD
Betaxolol—Asthenia—Capecitabine—prostate cancer	3.68e-05	0.000146	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—prostate cancer	3.65e-05	0.000145	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—prostate cancer	3.64e-05	0.000145	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—prostate cancer	3.64e-05	0.000144	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—prostate cancer	3.63e-05	0.000144	CcSEcCtD
Betaxolol—Urticaria—Prednisone—prostate cancer	3.63e-05	0.000144	CcSEcCtD
Betaxolol—Pruritus—Capecitabine—prostate cancer	3.63e-05	0.000144	CcSEcCtD
Betaxolol—Diarrhoea—Docetaxel—prostate cancer	3.62e-05	0.000144	CcSEcCtD
Betaxolol—Body temperature increased—Prednisone—prostate cancer	3.61e-05	0.000143	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—prostate cancer	3.6e-05	0.000143	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—prostate cancer	3.58e-05	0.000142	CcSEcCtD
Betaxolol—Oedema—Epirubicin—prostate cancer	3.57e-05	0.000142	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—prostate cancer	3.56e-05	0.000141	CcSEcCtD
Betaxolol—Infection—Epirubicin—prostate cancer	3.55e-05	0.000141	CcSEcCtD
Betaxolol—Cough—Doxorubicin—prostate cancer	3.53e-05	0.00014	CcSEcCtD
Betaxolol—Shock—Epirubicin—prostate cancer	3.51e-05	0.000139	CcSEcCtD
Betaxolol—Diarrhoea—Capecitabine—prostate cancer	3.51e-05	0.000139	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—prostate cancer	3.5e-05	0.000139	CcSEcCtD
Betaxolol—Dizziness—Docetaxel—prostate cancer	3.5e-05	0.000139	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—prostate cancer	3.5e-05	0.000139	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—prostate cancer	3.48e-05	0.000138	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—prostate cancer	3.47e-05	0.000138	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—prostate cancer	3.43e-05	0.000136	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.42e-05	0.000136	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—prostate cancer	3.41e-05	0.000135	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—prostate cancer	3.4e-05	0.000135	CcSEcCtD
Betaxolol—Dizziness—Capecitabine—prostate cancer	3.39e-05	0.000135	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—prostate cancer	3.37e-05	0.000134	CcSEcCtD
Betaxolol—Vomiting—Docetaxel—prostate cancer	3.37e-05	0.000134	CcSEcCtD
Betaxolol—Hypersensitivity—Prednisone—prostate cancer	3.36e-05	0.000134	CcSEcCtD
Betaxolol—Rash—Docetaxel—prostate cancer	3.34e-05	0.000133	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—prostate cancer	3.34e-05	0.000132	CcSEcCtD
Betaxolol—Dermatitis—Docetaxel—prostate cancer	3.33e-05	0.000132	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—prostate cancer	3.33e-05	0.000132	CcSEcCtD
Betaxolol—Headache—Docetaxel—prostate cancer	3.32e-05	0.000132	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—prostate cancer	3.3e-05	0.000131	CcSEcCtD
Betaxolol—Infection—Doxorubicin—prostate cancer	3.28e-05	0.00013	CcSEcCtD
Betaxolol—Asthenia—Prednisone—prostate cancer	3.28e-05	0.00013	CcSEcCtD
Betaxolol—Vomiting—Capecitabine—prostate cancer	3.26e-05	0.000129	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.25e-05	0.000129	CcSEcCtD
Betaxolol—Shock—Doxorubicin—prostate cancer	3.25e-05	0.000129	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—prostate cancer	3.24e-05	0.000129	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Betaxolol—Rash—Capecitabine—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Betaxolol—Pruritus—Prednisone—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Betaxolol—Dermatitis—Capecitabine—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—prostate cancer	3.22e-05	0.000128	CcSEcCtD
Betaxolol—Headache—Capecitabine—prostate cancer	3.21e-05	0.000127	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—prostate cancer	3.21e-05	0.000127	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—prostate cancer	3.21e-05	0.000127	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—prostate cancer	3.19e-05	0.000127	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—prostate cancer	3.18e-05	0.000126	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—prostate cancer	3.15e-05	0.000125	CcSEcCtD
Betaxolol—Nausea—Docetaxel—prostate cancer	3.14e-05	0.000125	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—prostate cancer	3.14e-05	0.000125	CcSEcCtD
Betaxolol—Diarrhoea—Prednisone—prostate cancer	3.12e-05	0.000124	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—prostate cancer	3.1e-05	0.000123	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—prostate cancer	3.09e-05	0.000123	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—prostate cancer	3.08e-05	0.000122	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—prostate cancer	3.08e-05	0.000122	CcSEcCtD
Betaxolol—Constipation—Epirubicin—prostate cancer	3.05e-05	0.000121	CcSEcCtD
Betaxolol—Pain—Epirubicin—prostate cancer	3.05e-05	0.000121	CcSEcCtD
Betaxolol—Nausea—Capecitabine—prostate cancer	3.04e-05	0.000121	CcSEcCtD
Betaxolol—Dizziness—Prednisone—prostate cancer	3.02e-05	0.00012	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.01e-05	0.000119	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—prostate cancer	2.99e-05	0.000119	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—prostate cancer	2.97e-05	0.000118	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—prostate cancer	2.95e-05	0.000117	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—prostate cancer	2.94e-05	0.000117	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—prostate cancer	2.91e-05	0.000115	CcSEcCtD
Betaxolol—Vomiting—Prednisone—prostate cancer	2.9e-05	0.000115	CcSEcCtD
Betaxolol—Rash—Prednisone—prostate cancer	2.88e-05	0.000114	CcSEcCtD
Betaxolol—Dermatitis—Prednisone—prostate cancer	2.88e-05	0.000114	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—prostate cancer	2.87e-05	0.000114	CcSEcCtD
Betaxolol—Headache—Prednisone—prostate cancer	2.86e-05	0.000114	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—prostate cancer	2.84e-05	0.000113	CcSEcCtD
Betaxolol—Pain—Doxorubicin—prostate cancer	2.83e-05	0.000112	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—prostate cancer	2.83e-05	0.000112	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—prostate cancer	2.82e-05	0.000112	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—prostate cancer	2.72e-05	0.000108	CcSEcCtD
Betaxolol—Nausea—Prednisone—prostate cancer	2.71e-05	0.000108	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—prostate cancer	2.63e-05	0.000104	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—prostate cancer	2.62e-05	0.000104	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—prostate cancer	2.61e-05	0.000104	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—prostate cancer	2.56e-05	0.000102	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—prostate cancer	2.53e-05	0.0001	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—prostate cancer	2.44e-05	9.7e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—prostate cancer	2.43e-05	9.66e-05	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—prostate cancer	2.37e-05	9.41e-05	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—prostate cancer	2.36e-05	9.37e-05	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—prostate cancer	2.34e-05	9.28e-05	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—prostate cancer	2.27e-05	9.01e-05	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—prostate cancer	2.26e-05	8.97e-05	CcSEcCtD
Betaxolol—Rash—Epirubicin—prostate cancer	2.25e-05	8.94e-05	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—prostate cancer	2.25e-05	8.93e-05	CcSEcCtD
Betaxolol—Headache—Epirubicin—prostate cancer	2.24e-05	8.88e-05	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—prostate cancer	2.18e-05	8.67e-05	CcSEcCtD
Betaxolol—Nausea—Epirubicin—prostate cancer	2.12e-05	8.42e-05	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—prostate cancer	2.1e-05	8.34e-05	CcSEcCtD
Betaxolol—Rash—Doxorubicin—prostate cancer	2.08e-05	8.27e-05	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—prostate cancer	2.08e-05	8.26e-05	CcSEcCtD
Betaxolol—Headache—Doxorubicin—prostate cancer	2.07e-05	8.22e-05	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—prostate cancer	1.96e-05	7.79e-05	CcSEcCtD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.07e-05	0.000126	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA4—prostate cancer	1.07e-05	0.000126	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TBXAS1—prostate cancer	1.07e-05	0.000126	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.07e-05	0.000125	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.06e-05	0.000124	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.05e-05	0.000124	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.05e-05	0.000123	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SULT2A1—prostate cancer	1.05e-05	0.000123	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.05e-05	0.000123	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA2—prostate cancer	1.04e-05	0.000122	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.04e-05	0.000122	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SULT1A1—prostate cancer	1.03e-05	0.000121	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCG5—prostate cancer	1.03e-05	0.000121	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MED12—prostate cancer	1.03e-05	0.000121	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.03e-05	0.000121	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GNG5—prostate cancer	1.02e-05	0.00012	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.01e-05	0.000119	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.01e-05	0.000118	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA1—prostate cancer	1.01e-05	0.000118	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1e-05	0.000118	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NAT2—prostate cancer	9.94e-06	0.000117	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTO1—prostate cancer	9.94e-06	0.000117	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HSD3B2—prostate cancer	9.94e-06	0.000117	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	9.91e-06	0.000116	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	9.87e-06	0.000116	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA3—prostate cancer	9.84e-06	0.000115	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	9.82e-06	0.000115	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—LPL—prostate cancer	9.71e-06	0.000114	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	9.64e-06	0.000113	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	9.63e-06	0.000113	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	9.56e-06	0.000112	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—LRP2—prostate cancer	9.53e-06	0.000112	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2C18—prostate cancer	9.53e-06	0.000112	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PLCB2—prostate cancer	9.53e-06	0.000112	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	9.53e-06	0.000112	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—LPL—prostate cancer	9.5e-06	0.000112	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	9.43e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	9.42e-06	0.000111	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HPGDS—prostate cancer	9.38e-06	0.00011	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	9.38e-06	0.00011	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—P4HB—prostate cancer	9.35e-06	0.00011	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2C19—prostate cancer	9.32e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	9.32e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	9.18e-06	0.000108	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	9.16e-06	0.000108	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ACHE—prostate cancer	9.1e-06	0.000107	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—prostate cancer	9.1e-06	0.000107	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	9.1e-06	0.000107	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC22A1—prostate cancer	9.09e-06	0.000107	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	9.08e-06	0.000107	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2A6—prostate cancer	9e-06	0.000106	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.99e-06	0.000106	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	8.96e-06	0.000105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	8.9e-06	0.000104	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	8.89e-06	0.000104	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SULT2A1—prostate cancer	8.86e-06	0.000104	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	8.75e-06	0.000103	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKR1C3—prostate cancer	8.75e-06	0.000103	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—prostate cancer	8.72e-06	0.000102	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MED12—prostate cancer	8.72e-06	0.000102	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PRKACB—prostate cancer	8.7e-06	0.000102	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GNG5—prostate cancer	8.65e-06	0.000102	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP17A1—prostate cancer	8.61e-06	0.000101	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	8.56e-06	0.000101	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—prostate cancer	8.53e-06	0.0001	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	8.34e-06	9.79e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA3—prostate cancer	8.33e-06	9.78e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA2—prostate cancer	8.21e-06	9.64e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.19e-06	9.61e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	8.16e-06	9.58e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—LEP—prostate cancer	8.14e-06	9.56e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	8.07e-06	9.47e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KDR—prostate cancer	7.98e-06	9.36e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—LEP—prostate cancer	7.96e-06	9.35e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HPGDS—prostate cancer	7.95e-06	9.33e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2C19—prostate cancer	7.9e-06	9.27e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	7.89e-06	9.26e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC5A5—prostate cancer	7.83e-06	9.19e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KDR—prostate cancer	7.8e-06	9.16e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	7.77e-06	9.12e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—prostate cancer	7.71e-06	9.05e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ACHE—prostate cancer	7.71e-06	9.05e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2E1—prostate cancer	7.65e-06	8.98e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2A6—prostate cancer	7.62e-06	8.95e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	7.6e-06	8.93e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.59e-06	8.91e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—BAD—prostate cancer	7.59e-06	8.91e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NQO1—prostate cancer	7.56e-06	8.88e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TH—prostate cancer	7.45e-06	8.75e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—BAD—prostate cancer	7.42e-06	8.71e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKR1C3—prostate cancer	7.41e-06	8.7e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP3A4—prostate cancer	7.38e-06	8.66e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PRKACB—prostate cancer	7.37e-06	8.66e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—APC—prostate cancer	7.35e-06	8.62e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	7.35e-06	8.62e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP17A1—prostate cancer	7.3e-06	8.57e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGF—prostate cancer	7.26e-06	8.53e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	7.26e-06	8.53e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1B1—prostate cancer	7.25e-06	8.51e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.2e-06	8.45e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—APC—prostate cancer	7.19e-06	8.44e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	7.19e-06	8.44e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	7.1e-06	8.34e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGF—prostate cancer	7.1e-06	8.34e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	7.05e-06	8.28e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GGT1—prostate cancer	7.02e-06	8.24e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—INS—prostate cancer	6.95e-06	8.16e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA2—prostate cancer	6.95e-06	8.16e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA1—prostate cancer	6.92e-06	8.12e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	6.9e-06	8.1e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP19A1—prostate cancer	6.82e-06	8e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	6.81e-06	8e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—INS—prostate cancer	6.8e-06	7.99e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	6.73e-06	7.9e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	6.69e-06	7.86e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	6.66e-06	7.82e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC5A5—prostate cancer	6.63e-06	7.79e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	6.58e-06	7.73e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—RXRA—prostate cancer	6.58e-06	7.72e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	6.55e-06	7.69e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	6.5e-06	7.63e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2E1—prostate cancer	6.48e-06	7.61e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	6.46e-06	7.58e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NQO1—prostate cancer	6.41e-06	7.52e-05	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	6.4e-06	7.51e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	6.39e-06	7.5e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	6.36e-06	7.47e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—COMT—prostate cancer	6.34e-06	7.44e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	6.32e-06	7.42e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	6.32e-06	7.42e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TH—prostate cancer	6.31e-06	7.41e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—prostate cancer	6.31e-06	7.41e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.27e-06	7.37e-05	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	6.26e-06	7.35e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	6.25e-06	7.34e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP3A4—prostate cancer	6.25e-06	7.34e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.22e-06	7.3e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ITPR1—prostate cancer	6.21e-06	7.29e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	6.19e-06	7.26e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	6.18e-06	7.26e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1B1—prostate cancer	6.14e-06	7.21e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	6.1e-06	7.16e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	6.05e-06	7.1e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	5.97e-06	7e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GGT1—prostate cancer	5.95e-06	6.98e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	5.93e-06	6.96e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMS—prostate cancer	5.86e-06	6.88e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA1—prostate cancer	5.86e-06	6.88e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	5.81e-06	6.82e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	5.8e-06	6.81e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—prostate cancer	5.8e-06	6.81e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	5.79e-06	6.79e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP19A1—prostate cancer	5.78e-06	6.78e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	5.7e-06	6.7e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—LPL—prostate cancer	5.69e-06	6.68e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	5.68e-06	6.67e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	5.66e-06	6.64e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	5.63e-06	6.61e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	5.58e-06	6.55e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—RXRA—prostate cancer	5.57e-06	6.54e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	5.51e-06	6.46e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.5e-06	6.45e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ERCC2—prostate cancer	5.45e-06	6.4e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.42e-06	6.36e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	5.41e-06	6.35e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—COMT—prostate cancer	5.37e-06	6.3e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—prostate cancer	5.34e-06	6.27e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	5.29e-06	6.21e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	5.28e-06	6.2e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ITPR1—prostate cancer	5.26e-06	6.17e-05	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	5.23e-06	6.14e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	5.18e-06	6.08e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.17e-06	6.07e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2—prostate cancer	5.17e-06	6.07e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	5.17e-06	6.07e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	5.14e-06	6.04e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTHFR—prostate cancer	5.12e-06	6.01e-05	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	5.11e-06	6e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	5.07e-06	5.95e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2—prostate cancer	5.06e-06	5.94e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	5.04e-06	5.92e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	5.03e-06	5.91e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PPARA—prostate cancer	5.03e-06	5.9e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	4.99e-06	5.86e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMS—prostate cancer	4.97e-06	5.83e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	4.93e-06	5.79e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—prostate cancer	4.91e-06	5.76e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	4.89e-06	5.74e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	4.88e-06	5.73e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	4.88e-06	5.72e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	4.86e-06	5.71e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—LPL—prostate cancer	4.82e-06	5.66e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	4.79e-06	5.62e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	4.77e-06	5.6e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	4.76e-06	5.59e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	4.75e-06	5.57e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CAV1—prostate cancer	4.73e-06	5.55e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1A1—prostate cancer	4.66e-06	5.47e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	4.64e-06	5.45e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EP300—prostate cancer	4.64e-06	5.45e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ERCC2—prostate cancer	4.62e-06	5.42e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EP300—prostate cancer	4.54e-06	5.33e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SRC—prostate cancer	4.51e-06	5.3e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SRC—prostate cancer	4.41e-06	5.18e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	4.39e-06	5.16e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	4.35e-06	5.11e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTHFR—prostate cancer	4.34e-06	5.09e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.3e-06	5.05e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.3e-06	5.05e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PPARA—prostate cancer	4.26e-06	5e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.26e-06	5e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—INS—prostate cancer	4.07e-06	4.78e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—prostate cancer	4.04e-06	4.75e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	4.03e-06	4.73e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CAV1—prostate cancer	4e-06	4.7e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CREBBP—prostate cancer	3.99e-06	4.68e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—prostate cancer	3.95e-06	4.64e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.95e-06	4.64e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	3.95e-06	4.63e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	3.87e-06	4.54e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.82e-06	4.49e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.78e-06	4.44e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	3.74e-06	4.39e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	3.65e-06	4.29e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CG—prostate cancer	3.65e-06	4.28e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NOS3—prostate cancer	3.57e-06	4.19e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—INS—prostate cancer	3.45e-06	4.05e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.43e-06	4.03e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CREBBP—prostate cancer	3.38e-06	3.97e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.36e-06	3.94e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—prostate cancer	3.32e-06	3.9e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.3e-06	3.87e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS2—prostate cancer	3.27e-06	3.84e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—prostate cancer	3.25e-06	3.81e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.21e-06	3.76e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6—prostate cancer	3.04e-06	3.57e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NOS3—prostate cancer	3.03e-06	3.55e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6—prostate cancer	2.97e-06	3.49e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTEN—prostate cancer	2.85e-06	3.35e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.8e-06	3.29e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CB—prostate cancer	2.79e-06	3.28e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS2—prostate cancer	2.77e-06	3.25e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.74e-06	3.22e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EP300—prostate cancer	2.72e-06	3.19e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTEN—prostate cancer	2.41e-06	2.83e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EP300—prostate cancer	2.3e-06	2.7e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.01e-06	2.36e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.7e-06	2e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKT1—prostate cancer	1.64e-06	1.93e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKT1—prostate cancer	1.39e-06	1.63e-05	CbGpPWpGaD
